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Summary. Single photon emission computed tomography
(SPECT) has been the cornerstone of nuclear medicine and today
it is widely used to detect molecular changes in cardiovascular,
neurological and oncological diseases. While SPECT has been
available since the 1980s, advances in instrumentation hardware,
software and the availability of new radiotracers that are creating
a revival in SPECT imaging are reviewed in this paper.
The biggest change in the last decade has been the fusion
of CT with SPECT, which has improved attenuation correction
and image quality. Advances in collimator design, replacement
of sodium iodide crystals in the detectors with cadmium zinc
telluride (CZT) detectors as well as advances in software and
reconstruction algorithms have all helped to retain SPECT as
a much needed and used technology.
Today, a wide spectrum of radiotracers is available for use
in cardiovascular, neurology and oncology applications. The
development of several radiotracers for neurological disor-
ders is briefly described in this review, including [123I]FP-CIT
(DaTSCAN™) available for Parkinson’s disease. In cardiology,
while technetium-99m labeled tetrofosmin and technetium-99m
labeled sestamibi have been well known for myocardial per-
fusion imaging, we describe a recently completed multicenter
clinical study on the use of [123I]mIBG (AdreView™) for imag-
ing in chronic heart failure patients. For oncology, while bone
scanning has been prevalent, newer radiotracers that target can-
cer mechanisms are being developed. Technetium-99m labeled
RGD peptides have been reported in the literature that can be
used for imaging angiogenesis, while technetium-99m labeled
duramycin has been used to image apoptosis.
While PET/CT is considered to be the more advanced tech-
nology particularly for oncology applications, SPECT continues
to be the modality of choice and the workhorse in many hospitals
and nuclear medicine centers. The cost of SPECT instruments
also makes them more attractive in developing countries where
the cost of a scan is still prohibitive for many patients.
1. Introduction to molecular imaging
There are two major molecular imaging modalities which
are used in nuclear medicine today, namely single pho-
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ton emission computed tomography (SPECT or less com-
monly known as SPET) and positron emission tomogra-
phy (PET). Both techniques use radiolabeled molecules to
probe molecular processes that can be visualized, quanti-
fied and tracked over time, thus allowing the discrimination
of healthy from diseased tissue with a high degree of con-
fidence. The imaging agents use target-specific biological
processes associated with the disease being assessed both at
the cellular and subcellular levels within living organisms.
The impact of molecular imaging has been on greater under-
standing of integrative biology, earlier detection and charac-
terization of disease, and evaluation of treatment in human
subjects [1–3]. Additionally, the power of these techniques
has resulted in better estimation of disease staging [4, 5] and
has also aided drug development programmes [6, 7].
Out of the two techniques, SPECT is the most established
modality and standard imaging procedures have been widely
available in most hospitals since the early 1990s. Although
SPECT has been used to investigate many applications in
neurology and oncology, the majority of SPECT proced-
ures are performed in the field of cardiology, particularly in
the assessment of coronary perfusion and myocardial viabil-
ity [8].
The radiotracers used in SPECT emit gamma rays, as op-
posed to PET isotopes which are positron emitters, such as,
11C (T1/2 = 20.4 min), 18F (T1/2 = 110 min). The SPECT ra-
diotracers have relatively long half-lives from a few hours to
a few days (99mTc T1/2 = 6.0 h; 111In T1/2 = 67.3 h; 123I T1/2 =
13.3 h; 201Tl T1/2 = 72.9 h) and their use can be tailored to
the specific application being investigated. As well as de-
velopment of imaging agents [9, 10], there has been an even
greater emphasis on the development of new SPECT imag-
ing systems with increased sensitivity and improve image
quality and resolution [11]. It is anticipated that advance-
ment in both directions will greatly influence the future of
molecular medicine.
In most countries today, the number of SPECT cameras
exceeds the number of PET systems and for developing na-
tions like India and China, SPECT availability is as high as
4–5 times more than PET. As advances in PET and hybrid
PET imaging (PET/CT or PET/MRI) come into wider use,
it is natural to ask if the modality of the future will be dom-
inated by PET or will there be a role for SPECT imaging as
well. This article reviews SPECT radiotracers available and
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in development today that are critical to the continuing role
of SPECT in diagnosis and therapy monitoring.
2. Role of SPECT
Since the first use of the Anger camera in the 1950s and the
advent of the modern SPECT camera in the 1970s, SPECT
imaging has become widely accepted in the diagnosis, mon-
itoring and evaluation of diseases. Some of the advances that
have fuelled this growth in the last couple of decades have
been: (1) Improvements in SPECT collimators from simple
parallel to pin hole and fan beam collimators; (2) Develop-
ment from single-head to multihead cameras; (3) Improve-
ments in detectors to use cadmium zinc telluride (CZT) that
allow direct conversion of gamma rays into electrical signals
and have higher intrinsic resolution; (4) Hybrid SPECT/CT
systems that have improved image quality; (5) New SPECT
radiotracers that target disease mechanisms for more sensi-
tive and specific detection.
2.1 Image quality
Image quality in SPECT is determined by attenuation, scat-
ter, spatial and energy resolution and statistical fluctuations
(image noise) and contrast (target to background ratio).
The integration of CT with SPECT has allowed for atten-
uation correction that has improved the image quality, and
the CT also provides fair anatomical images [12]. The CT
image is acquired prior to the SPECT image and produces
an attenuation map of the spatial distribution of the attenu-
ation coefficients. However, in a SPECT/CT system, patient
movement between the two acquisitions can lead to incorrect
attenuation correction and misregistration.
Scatter in SPECT images can reduce image contrast,
lead to inaccurate quantification and even for artifacts to
be seen in a region of no activity or outside the patient.
Various scatter correction algorithms have been reviewed
previously [13], including scatter model based correction
strategies and strategies based on iterative reconstruction al-
gorithms.
Image quality is a tradeoff between resolution, sensitiv-
ity, field of view (FOV) and detector area [14]. While overall
image quality in PET is considered superior for many appli-
cations, the new advances in instrumentation and software
have made SPECT highly valued.
2.2 PET vs. SPECT
SPECT spatial resolution stands today at ∼ 10 mm while
PET spatial resolution is at ∼ 5 mm. Despite the challenges
of spatial resolution in SPECT, a comparison of PET vs.
SPECT studies shows that SPECT continues to be a modal-
ity of choice in various clinical applications, especially in
cardiology.
2.2.1 Cardiology PET vs. SPECT
SPECT is well established as the modality of choice in my-
ocardial perfusion imaging. The clinical guidelines on use
of radionuclides from the American College of Cardiology
and the American Heart Association [15] report that average
sensitivity is 87% for detecting angiographically significant
coronary artery disease, while average specificity is 73%.
The guidelines also recommend the use of [18F]FDG PET to
assess myocardial viability.
2.2.2 Oncology PET vs. SPECT
For oncology applications, PET is the modality of choice
with multiple radiotracers being used for imaging ([18F]FDG
for glucose metabolism, [18F]FLT for cell proliferation,
18F labeled RGD for angiogenesis, [18F]ethylcholine for
prostate, etc.). However, SPECT continues to be the modal-
ity of choice in bone scintigraphy. In a study on the use of
[18F]FDG PET vs. SPECT (using 99mTc-HMDP) in detecting
bone metastases from breast cancer [16], a lesion-by-lesion
analysis in 15 patients showed that SPECT was more sensi-
tive (85%) compared to PET (17%) and the overall accuracy
of SPECT was higher (96%) compared to PET (85%).
2.2.3 Neurology PET vs. SPECT
It has been well established that 99mTc-hexamethylpropyl-
eneamine oxime (99mTc-HMPAO) SPECT and [18F]FDG
PET can be used to detect cerebral perfusion and metabolic
abnormalities seen in Alzheimer’s disease. In a direct
comparison of spatially normalized PET and SPECT in
Alzheimer’s [17], it was shown that there was a high cor-
relation in the number of abnormal voxels seen in PET and
SPECT in specific regions of the brain (temporoparietal and
posterior cingulate association cortices). For neurological
disorders like Alzheimer’s and Parkinson’s, specific radio-
tracers that target the disease mechanism ([18F]PIB to detect
amyloid plaques, [123I]FP-CIT (ioflupane) to detect Parkin-
son’s described later in this article) will impact the clinical
workflow. For SPECT to be useful in neurology, 123I is
preferred for improved blood brain barrier penetration as
compared to the larger 99mTc chelated molecules.
2.2.4 SPECT – the right choice?
In a commentary on the future of nuclear medicine [18], the
authors argue that while SPECT technology faces competi-
tion from PET, the role of SPECT in clinical investigations
will continue. The wide availability of SPECT scanners,
comparatively simpler and less expensive infrastructure re-
quirements, and lower cost of SPECT scans will continue to
drive the use of SPECT across the world.
3. Radiolabeling
3.1 Technetium-99m labeling
There are several reviews on technetium published [19–21],
and we refer the readers to them for a detailed review of this
element. In this section, we provide a brief summary high-
lighting some of the key aspects in the design of radiotracers
based on technetium-99m.
Technetium-99 exists commonly as two isomers: 99gTc
and 99mTc. The longer-lived 99gTc is used to study the co-
ordination chemistry of technetium and verify the struc-
tures of compounds of technetium. 99mTc, its most widely
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Fig. 1. Snapshot of technetium com-
plexes, which have been characterized
by X-ray crystallography. Cambridge
Crystallographic Reference numbers
are included under each complex and
the oxidation state of the technetium
ion is presented in parentheses.
studied isotope, has become the mainstay of diagnostic nu-
clear medicine. 99mTc (as [99mTc]pertechnetate) is produced
by the decay of 99Mo, and is available commercially via elu-
tion (with 0.9% saline) of alumina columns that have 99Mo
adsorbed on them.
The synthesis of a 99mTc radiotracer typically involves
three components:
I. Pertechnetate (99mTcO4−).
II. A reducing agent (e.g. Sn(II), Fe(II), Cu(I), as well as
non-metallic reducing agents such as dithionite, borohy-
dride).
III. and a chelator.
The design of chelators is critical in the development of
technetium radiotracers and consequently there has been
significant work performed synthesizing chelators which
rapidly complex with technetium to form stable complexes.
Understanding the coordination chemistry of technetium is
therefore critical in the development of new chelators.
In spite of the challenges of handling 99gTc (a long-lived
isotope requiring dedicated chemistry laboratories) a large
number of technetium complexes have been reported, many
of which have been characterized by crystallography (there
are greater than 700 X-ray structures of technetium com-
plexes on the Cambridge Crystallographic Database) [22].
Whilst the chemistry of technetium is dominated by
the +5 oxidation state, it is clearly evident that stable
technetium complexes with a variety of other oxidation
states can be prepared. Different chelators stabilize differ-
ent oxidation states and this has been used in develop-
ing technetium complexes with differing physicochemical
properties (e.g. lipophilicities and charge of the complex).
Fig. 1 displays a snapshot of some of the technetium com-
plexes, which have been characterized by X-ray crystal-
lography, highlighting the variety of coordination environ-
ments, which can be tolerated by technetium. The Cam-
bridge Crystallographic Reference numbers are included
under each complex and coordinates are available (as a cif
file) from ccdc.cam.ac.uk.
3.2 Iodine-123 labeling
Whilst there are many isotopes of iodine, only one stable
isotope, iodine-127 is found in nature. Four radioisotopes
(123I, 124I, 125I, 131I) have been widely used for labeling both
small and large molecules. Whilst this section focuses on
iodine-123, the chemistry strategies for the other isotopes
are essentially the same [23].
Iodine-123 is produced at a cyclotron and there are sev-
eral different production routes, but typically it is formed
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Fig. 2. Nucleophilic substitution to label with 123I.
using highly enriched 124Xe as a target. Typically it is sup-
plied as Na123I in a 0.1 M NaOH solution. The labeling of
compounds with iodine-123 can be achieved either by nucle-
ophilic or electrophilic substitution.
3.2.1 Nucleophilic substitution
The simplest way to introduce iodine-123 into a small
molecule is via isotopic exchange (Fig. 2). This results in
regiospecific substitution (usually catalyzed by copper or
gold) generally with good radiochemical yields. Purification
of the radiolabeled product tends to be simple, but since
the iodine-127 precursor cannot be chemically separated
from the radiolabeled derivative, lower specific activities
are achieved. Higher specific activities can be achieved, but
purification is required (typically HPLC). Similar halogen-
exchange reactions can be achieved with high regiospecific
substitution from the corresponding chlorine or bromine
containing compounds – however radiochemical yields tend
to be lower.
3.2.2 Electrophilic substitution
Electrophilic iodination chemistry is the predominant ap-
proach for the introduction of iodine-123 into biomolecules.
This requires the oxidation of iodide, which is easily
achieved since the oxidizing potential of iodide is low
and this allows for the direct formation of an electrophilic
species in which the iodine is oxidized to I+. A number of
oxidizing agents have been used in iodine-123 chemistry
for the oxidation of iodide to I+ (peracids, iodine mono-
halide, N-chloroamides, iodogen) and these are described
elsewhere [23].
Iodo-deprotonation
Iodo-deprotonation is generally limited to arenes which are
activated for electrophilic substitution (Fig. 3). The pres-
ence of tyrosine residues in peptides means that this may be
a simple and fast approach to label the compound. Whilst
this method is relatively simple, if the compound to be la-
beled is asymmetrical, a mixture of compounds may be
formed [24].
Fig. 3. Electrophilic substitution (iodo-deprotonation).
Fig. 4. Iodo-destannylation and iodo-deboronation.
Fig. 5. Iodo-destannylation with retention of configuration across
a double bond.
Site specific electrophilic substitutions
Two strategies for labeling compounds with high regiospeci-
ficity are shown in Fig. 4. Iodo-destannylation and iodo-
deboronation have become popular since they generally re-
sult in good radiochemical yields and can often be per-
formed at room temperature [25, 26].
This high selectivity using trilalkyltin derivatives facili-
tates the introduction of the iodine-123 to label alkenes with
retention of configuration across the double bond [27] as
seen in Fig. 5.
Indirect labeling
Methods for labeling biomolecules such as peptides should,
in general, be mild and rapid affording high radiochemical
yields. However, whilst the previous methods afford simple
and rapid labeling, the presence of oxidizing agents required
to generate “I+” may not make them suitable for labeling
biomolecules (which are sensitive to oxidizing agents). To
overcome this obstacle, it is possible to pre-label a small mo-
lecular weight synthon with iodine-123 and then to perform
the coupling to the sensitive biomolecule using milder (non-
oxidizing) conditions. Fig. 6 depicts the formation of a ra-
dioiodinated active ester, which is coupled on to an amine
residue (e.g. lysine) of a biomolecule.
4. SPECT radiotracers for neurology
SPECT can be used non-invasively to indirectly monitor
changes in neurotransmitter concentration, provided that (i),
a radiotracer specific and selective for the system of inter-
est is available, and (ii), the radiotracer binds to the same
site as the endogenous ligand, or neurotransmitter. Over the
last 15 years, many studies have demonstrated the use of
SPECT to non-invasively measure acute changes in neuro-
transmitter levels in vivo [28], initially assuming a direct
competition between the radiotracer and the endogenous
neurotransmitter at the binding site. The basic concept of the
Brought to you by | University of Queensland - UQ Library
Authenticated
Download Date | 11/27/15 7:50 AM
Radiotracers for SPECT imaging 99
Fig. 6. Labeling peptides
with iodinated synthons.
Table 1. Common SPECT radiotracers and radiotracers available for neurology.
Target SPECT radiotracer/ligand
Regional cerebral perfusion 99mTc-bicisate (ECD, Neurolite™),
99mTc-exametazime (HMPAO, Ceretec™),
[123I]iodoamphetamine ([123I]IMP)
Cerebrospinal fluid kinetics 111In-Pentetate
Phosphatidylserine – dementia 99mTc-HYNIC – annexin V
Dopamine D2, D3 receptors [123I]iodobenzamide (IBZM), [123I]epidepride
Dopamine reuptake transporter [123I]ioflupane, [123I]altropane, 99mTc-TRODAT
Peripheral benzodiazepine receptor (PBR) [123I]PK11195
Amyloid [123I]IMPY
Serotonin teuptake transporter (SERT) [123I]IDAM, [′123I]ADAM
GABA receptor [123I]iomazenil
“occupancy model” predicts that uptake/retention of tracer
levels of a specific radioligand at the site of its receptor will
be inversely related to the local concentration of the com-
peting neurotransmitter. However, because the status of the
receptor (availability due to up- or down-regulation, inter-
nalization, altered affinity states) may also change with the
stimulus leading to the change in the neurotransmitter con-
centration, each combination of receptor, radioligand, neu-
rotransmitter and stimulus must be fully understood before
such determinations can be made routinely. Such a discus-
sion is unfortunately beyond the scope of this general review
of radioligands for SPECT imaging.
An early challenge of the SPECT modality was to
design a radiotracer that crossed the intact blood–brain-
barrier (BBB) to permit imaging of the brain. Previously,
hydrophilic radiotracers like 99mTc-DTPA (pentetate) or
[99mTc]pertechnetate, which would normally be excluded by
the blood brain barrier (BBB), were used to detect areas
where the BBB had been compromised (for example, at
the site of an intracranial tumor). More recently, lipophilic
molecules and complexes have been designed that can cross
the BBB, either by passive diffusion or by facilitated trans-
port. Once inside the brain, various targeting or retention
mechanisms can be employed to allow selective retention at
the diagnostic target while allowing background clearance
of unbound radioactivity.
The increase in neurological applications for SPECT
over the last decade has been greatly aided by the signifi-
cant improvement in data acquisition (hardware technol-
ogy), data quantification (model-based methodology) and
the growing number of available SPECT metabolic radio-
tracers and receptor-specific radiotracers. Table 1 lists the
more common SPECT radiotracers/ligands and their in-
tended targets in clinical neurology, with structures shown in
Fig. 7. A more detailed review can be found in [29].
4.1 Cerebrovascular diseases
In the early 1980s, N-isopropyliodoamphetamine radiola-
beled with iodine-123 was introduced as one of the first
radiotracers that crossed the BBB and was retained approxi-
mately in proportion to regional cerebral perfusion. Reten-
tion was thought to be due to conversion to a less lipophilic
form of the molecule, possibly by N-demethylation, within
the brain. The images were however degraded as a re-
sult of the slow diffusion of radioactivity from the lungs,
which took up a large proportion of the administered activ-
ity immediately after injection.Subsequently, complexes of
technetium were developed e.g., 99mTc-exametazime (HM-
PAO, Ceretec™) and 99mTc-bicisate (Neurolite™), which be-
have in a similar manner (passive uptake followed by in-
tracerebral conversion to a less lipophilic, less diffusible
form and subsequently trapped intracellularly, in propor-
tion to the blood flow). Although assessment of cerebral
blood flow using SPECT radiotracers has provided clini-
cal diagnostic information, the SPECT technique does not
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Fig. 7. Common SPECT radiotracers for neurology applications.
provide high resolution images and the data are not opti-
mal for the quantitative estimation of the rate of cerebral
blood flow and perfusion. The two technetium-99m radio-
tracers, 99mTc-exametazime and 99mTc-bicisate, are however
frequently used for the assessment of regional cerebral per-
fusion in neurological diseases, replacing the less convenient
xenon-133 gas or solution in this role.
4.2 Alzheimer’s disease (amyloid ligands)
Alzheimer’s disease (AD) is the most important and com-
mon degenerative brain disorder where a person shows pro-
gressive memory loss and decrease in cognitive function.
AD is characterized by the presence of abundant amyloid
plaques in the brain. Thus, in vivo imaging agents targeting
amyloid plaques might serve as suitable markers for mon-
itoring the amyloid burden, following the disease progres-
sion and further provide indication for therapeutic interven-
tion. Several research groups have studied biomarkers for
imaging amyloid plaques in the brain [30, 31]. [123I]IMPY,
a modified thioflavin derivative is a novel agent displaying
high binding for amyloid plaques and favorable brain up-
take kinetics in rodents. Seibyl et al. [32] have shown that
this radiotracer is a good candidate for the detection of amy-
loid plaques in human Alzheimer’s subjects when used with
SPECT.
4.3 Parkinson’s disease (dopamine transporter)
Parkinson’s disease is a degenerative condition charac-
terized by tremor, hypokinesis and rigidity. Following
the release of the neurotransmitter dopamine into the
synapse, the dopamine is transported back into the pre-
synaptic nerve terminal by a specific dopamine transporter
(DAT) present on the pre-synaptic plasma membrane. Co-
caine and its analogues bind to this transporter, block
the reuptake of dopamine, and increase the intra-synaptic
dopamine levels. A large number of radiolabeled DAT lig-
ands have been developed based on the chemical struc-
ture of cocaine because of its relatively high affinity for
the DAT. These include radiotracers such as [123I]β-CIT
(N-methyl-2β-carbomethoxy-3β-(4-iodophenyl) tropane),
[123I]IPT (N-(3-iodopropen-2-yl)-2β-carbomethoxy-3β-(4-
chlorophenyl) nortropane), [123I]PE2I (N-(3-iodoprop-(2E)-
enyl)-2β -carbomethoxy-3β -(4-methylphenyl)nortropane),
[123I]2β-carbomethoxy-3β-(4-fluorophenyl)-n-(1-iodoprop-
1-en-3-yl)nortropane (altropane) and [123I]N-(3-fluoroprop-
yl)-2β-carbomethoxy-3β-(4-iodophenyl)nortropane ([123I]-
FP-CIT; [123I]ioflupane). [123I]Ioflupane is routinely avail-
able commercially as DaTSCAN™ and is a SPECT radio-
tracer that binds to the pre-synaptic dopamine transporter
to give images of the normal striata (Fig. 9a). In cases of
striatal dopaminergic deficit (such as are seen in Parkinsons
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Fig. 8. Regional cerebral perfu-
sion images obtained with Cere-
tec™. Note: Hypoperfused region
at the bottom right of these im-
ages from a stroke patient (cour-
tesy: GE Healthcare).
Fig. 9. DaTSCAN [123I]ioflupane images of human striata. (a) Nor-
mal scan shows characteristic comma shape. (b) Striatal dopaminergic
deficit seen where comma shape degrades.
disease and Dementia with Lewy Bodies) the characteristic
symmetrical “comma” shape of the two striata usually be-
comes asymmetric and/or degraded to the shape of a “full
stop” (Fig. 9b).
The technetium-99m labeled TRODAT (or tropantiol),
like ioflupane, is a tropane analogue of cocaine and sim-
ilarly, binds to the dopamine transporter. On the basis of
a N2S2 chelating agent, known as bisaminoethanethiol
(BAT), 99mTc-TRODAT-1 was developed for SPECT imag-
ing studies [33]. The brain uptake of this technetium-99m
complex is however lower than that of [123I]Ioflupane, so the
convenience of the “cold kit” presentation is balanced by the
reduced image quality.
4.4 Dopamine receptors
D1 and D2 receptors are highly concentrated in the stria-
tum and a number of antagonist radiotracers have been in-
vestigated. This extensive research in this field is in part
due to the successful discovery that the binding of the
D2 receptor radiotracer, [123I]IBZM, is particularly sensitive
to changes in dopamine levels [34]. [123I]IBZM has been
shown to be useful for semi-quantitative imaging of stri-
atal D2 dopamine receptors and for estimating their block-
ade by neuroleptics. Thus, it may improve drug monitor-
ing in psychiatric patients [35]. The availability of iodine-
123-labeled post-synaptic, and technetium-99m-labeled pre-
synaptic dopaminergic radiotracers, affords the possibility
of dual-isotope studies of this important region of the brain.
4.5 Serotonin transporter
123I-labeled IDAM and ADAM are potent inhibitors of the
serotonin reuptake transporter (SERT), based on the parent
compound, a phenylthiophenyl derivative known as 403U76.
They possess high selectivity and affinity for SERT over
norepinephrine and dopamine transporter binding sites. Ac-
cording to the initial human studies, [123I]ADAM localizes
in the hypothalamus, a region known to have high SERT
concentration. [123I]ADAM is superior to [123I]IDAM as
a SPECT imaging agent for SERT in the brain [36].
4.6 Neuroinflammation
Peripheral benzodiazepine binding sites (PBBS) are present
at low levels in the normal brain. These sites are highly
expressed in vivo by activated microglia, which are asso-
ciated with CNS inflammation in a wide range of patholo-
gies. In combination with MRI, to aid with anatomical
definition, SPECT imaging using the PBBS-selective ligand,
[123I]PK11195 provides a generic indicator of active disease
in the brain and, to date, has been used in clinical studies
of stroke, multiple sclerosis, dementia, Parkinson’s disease,
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Huntington’s chorea, epilepsy and schizophrenia [37]. How-
ever, this ligand, along with a 11C-labeled version for PET,
suffers from poor brain uptake. The radiotracers most widely
used for imaging central benzodiazepine-binding sites are
based on the antagonist, Ro-15-1788 (flumazenil). The 123I
labeled analogue, Iomazenil, binds mainly to an α1 subtype
of the GABAA receptors in the medial occipital cortex, fol-
lowed by other cortical areas.
The neuropharmacological data obtained from receptor-
specific SPECT studies can additionally help in increas-
ing knowledge about potential therapeutic targets for novel
pharmaceutical agents by determining their dose/occupancy
profile. This can be done using the radiolabeled drug under
investigation or by monitoring its effects on the binding of
an established radiotracer. In using the radiolabeled drug, re-
gional brain pharmacokinetic data are obtained within a very
short time frame. Alternatively, by quantifying the phar-
macology and the effects of an experimental drug on the
specific binding of an established radiotracer, we can de-
velop an understanding of the relationships between the
drug’s efficacy, plasma concentration and receptor occu-
pancy. As the number of PET/SPECT centers grows, ap-
plications of the use in clinical neurology will increase for
early and/or presymptomatic diagnosis of diseases. As more
target-specific radiotracers and ligands are developed, the
use of these in clinical research and drug development will
help determine optimal drug dosing regimes and elucidate
the down-stream effect of drug actions.
5. SPECT radiotracers for cardiovascular
disease
The current focus of cardiovascular medicine is on early
detection and prevention of disease. Worldwide, coronary
artery disease (CAD) is the single most important cause of
morbidity and mortality. The most common SPECT radio-
tracers used in cardiovascular imaging are shown in Fig. 10.
5.1 Myocardial perfusion imaging
Radionuclide myocardial perfusion imaging during exer-
cise or pharmacological stress and at rest is widely used
for diagnosis of ischemic heart disease [38, 39]. The un-
derlying principle is that under conditions of stress, the
Fig. 10. Most common 99mTc radiotracers used in cardiovacscular imaging.
diseased myocardium receives less blood flow than normal
myocardium. Specific radiotracers can be administered that
indicate the reduced blood flow e.g. 99mTc-tetrofosmin (My-
oview, GE Healthcare), 99mTc-sestamibi (Cardiolite, Bristol-
Myers Squibb).
5.1.1 Myoview™ (technetium (99mTc) tetrofosmin)
Imaging with Myoview™ is useful in the diagnosis and lo-
calization of regions of reversible myocardial ischemia in
the presence or absence of infarction. Its characteristic high
target to background ratio provides clear images [40] indi-
cating regions of low perfusion. It also demonstrates good
sensitivity, specificity and diagnostic accuracy.
The structural formula of Myoview™ is shown in Fig. 10
and the radiotracer technetium-99m is chelated by two 1,2-
bis[di-(2-ethoxyethyl)phosphino] ethane ligands.
5.1.2 Cardiolite (technetium (99mTc) sestamibi)
It is a lipophilic monocationic complex of technetium(I)
with the ligand methoxyisobutylisonitrile (MIBI) [41].
When injected intravenously into a patient, it distributes
in the myocardium proportionally to the myocardial blood
flow. It was the first successful 99mTc-labeled substitute for
[201Tl]thallous chloride for myocardial perfusion imaging
and diagnosis of myocardial infarction. Although it shares
with Tl+ the positive charge, supposed to be a prerequisite
for transport by Na+/K+-ATPase (Na+/K+ Pump), its mech-
anism of uptake in myocytes has been shown to be largely
different from that of Tl+. This is to date the most successful
and most intensively used SPECT radiotracer.
5.2 [123 I]mIBG imaging in heart failure
Metaiodobenzylguanadine (mIBG) or Iobenguane was de-
veloped almost 30 years ago at the University of Michi-
gan as an imaging agent for pheochromocytoma. mIBG
accumulates in the adrenergic nerve terminals via the nore-
pinephrine transporter system. While [123I]mIBG was orig-
inally developed for imaging adrenergic tumors, various
studies in the last 30 years [42–46] have shown [123I]mIBG
to be very useful in study of the sympathetic innervations of
the heart.
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A review of the literature [47] on [123I]mIBG showed
that over 30% of publications have focused on the use
of mIBG in cardiac applications, especially from Japan
where [123I]mIBG was available for use. Semi-quantitative
parameters used to measure mIBG uptake include early
and late heart-to-mediastinum (H/M) ratios and myocardial
washout. While there have been many clinical studies that
show that H/M ratios and myocardial washout could have
prognostic significance, some clinical studies have failed to
show any prognostic significance of these measures. How-
ever, a recent meta-analysis [48] and the results of the large
multicenter ADMIRE-HF (AdreView Myocardial Imaging
for Risk Evaluation in Heart Failure) [49] have provided
conclusive results on the benefits of using [123I]mIBG.
The meta-analysis [48] used 18 studies with a total of
1755 patients reported in the literature between 1999 and
2005 (except one study from 1992). As there was signifi-
cant heterogeneity, the 3 best quality studies were used for
a subset meta-analysis and the pooled hazard ratio for a car-
diac event and late H/M was 1.98 (p < 0.001). Myocardial
washout was a significant prognostic factor in predicting
cardiac death (hazard ratio = 1.72, p = 0.006) and cardiac
events (hazard ratio = 1.08, p < 0.001). The ADMIRE-HF
was a prospective study of 961 heart failure patients fol-
lowed up over 2 years that evaluated the prognostic value
of [123I]mIBG in predicting cardiac events. The hazard ratio
for H/M was 0.40 (p < 0.001); the significant contributors
to the multivariable model were H/M, LVEF, B-type natri-
uretic peptide, and New York Heart Association functional
class.
In cardiac [123I]mIBG imaging, it has been well vali-
dated that the choice of collimator can impact the image
quality and subsequent uptake parameters like H/M and
washout [50]. It is preferred to use a medium energy col-
limator that prevents septal penetration of the high energy
photons that come from 123I (2.87% photons have an energy
more than 400 keV). This can improve the image quality by
reducing scatter and thus improve the quantitative accuracy
of H/M ratios.
6. SPECT and oncology
Bone scanning is clinically important for patients in whom
detection of cancer that has spread to the bone would re-
sult in treatment changes. This includes patients with breast,
prostate and lung cancer. 99mTc-MDP planar bone scanning
or [18F]FDG PET/CT have been routinely used to scan bone
metastases [51, 52]. Although whole body SPECT imaging
with 99mTc-MDP is more sensitive than planar bone imag-
ing, routine clinical whole body SPECT imaging is not per-
formed because of the long image acquisition time required.
The past decade has seen the invention of many alterna-
tives to [18F]FDG that target specific aspects of tumor bi-
ology. These targets include molecular biomarkers such as
growth factor receptors, protein kinases, specific receptor
over-expression or biological events such as angiogenesis,
apoptosis, hypoxia and tumor proliferation. Many focused
efforts were reported for developing SPECT radiotracers for
angiogenesis and apoptosis and the most promising radio-
tracers are discussed here.
6.1 SPECT imaging of angiogenesis
Angiogenesis is the formation of new blood vessels through
capillary sprouting from pre-existing vasculature. Angio-
genesis plays a key role in the growth and metastatic
potential of solid tumors [53, 54]. Tumor growth beyond
a 1–2 mm3 volume requires an independent vasculature for
the cellular supply of oxygen and nutrients and removal
of waste products [55]. Consequently, tumors that outgrow
their existing blood supply frequently display oxygen de-
ficiency (hypoxia) that can trigger the secretion of various
pro-angiogenic growth factors, such as, vascular endothe-
lial growth factors (VEGFs) for initiating new blood vessel
growth [53]. Binding of VEGFs to the VEGF family of re-
ceptors (VEGFR) initiates a signaling cascade that promotes
the proliferation, migration and survival of endothelial cells,
ultimately leading to angiogenesis [56, 57]. VEGF radiola-
beled with 64Cu has been reported for small animal PET
imaging of VEGF receptor expression in vivo [58, 59].
An indirect and better approach to angiogenesis imag-
ing has focused on radiotracers targeting the αvβ3 class of
cell adhesion molecule integrins [60]. Integrin αvβ3 recep-
tors are significantly upregulated in endothelial cells during
angiogenesis but not in mature vessels or non-neoplastic ep-
ithelium [61–63]. Integrin αvβ3 is also expressed in a variety
of tumor cells, including melanoma, late-stage glioblastoma,
ovarian, breast and prostate cancer [64]. The ability to vi-
sualize and quantify integrin αvβ3 expression in vivo would
allow for appropriate selection of patients for anti-integrin
treatment and also for treatment monitoring in such patients.
Integrins are known to bind to peptides with exposed
arginine-glycine-aspartate (RGD) sequence and labeling of
the αvβ3 integrin with 99mTc-RGD peptide provides a po-
tential tool for imaging angiogenesis [65, 66]. It has been
shown in a previous study in females with histologically
proven breast cancer that the detection of malignant breast
tumors is feasible and efficient by scintigraphic imaging
with 99mTc-RGD peptide [67, 68]. Fig. 11 shows the struc-
ture of NC100692 (maraciclatide), the RGD peptide that has
been labeled with technetium for the study in breast can-
cer [67].
Fig. 12 shows the characteristic annular uptake of the
RGD peptide labeled with technetium-99m. As the exact
role of αvβ3 in the context of angiogenesis still is a matter
of debate, more information on the correlation of αvβ3 ex-
pression and other potential targets for antiangiogenic drugs,
like MMPs and VEGF receptors, is needed, in order to eval-
uate, if imaging of αvβ3 expression really is a valid sur-
rogate parameter for angiogenic activity. Other targets ex-
clusively expressed on activated endothelial cells like α5β1
might eventually be better suited for imaging of angiogen-
esis. Moreover, imaging of αvβ3 expression for assessment
of therapeutic response or angiogenic activity will have to
compete with “conventional” imaging methods of therapy
response and angiogenesis, like [18F]FDG PET and DCE
MRI/DCE CT.
6.2 SPECT imaging for apoptosis
Apoptosis (programmed cell death) plays a critical role in
the homeostasis of multicellular organisms and non-invasive
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Fig. 11. Structure of the -RGD peptide, which has been labeled with technetium for a study of angiogenesis in breast cancer patients [67].
Fig. 12. 99mTc-maraciclatide study showing SPECT/CT registration. Primary cancer seen in right lung (note annular uptake and necrotic center).
Right lung also shows pulmonary effusion.
in vivo imaging of cell death has important clinical diagnos-
tic and prognostic value. During apoptosis, it is well docu-
mented that cell surface exposure of phospholipids such as
phosphatidylserine (PS) and phosphatidylethanolamine (PE)
occurs [69]. In viable cells these phospholipids are almost
exclusively found on the inner leaflet of the plasma mem-
brane and this asymmetry is maintained by active energy
dependent enzymes and translocases [70]. However, during
apoptosis the mechanisms that maintain this asymmetry are
lost and the redistribution of phospholipids is actively fa-
cilitated by scramblases [71]. Therefore, the externalisation
of PE and PS is a universal marker for those cells that are
committed to the apoptotic pathway leading to cell death.
A vast majority of the work on apoptosis targeted ra-
diotracers has focused on Annexin V and its derivatives
(Fig. 13) [72]. Annexin V is a member of the calcium and
phospholipid binding superfamily of Annexin proteins that
displays selective, nanomolar affinity (Kd ∼ 0.5–7 nM) to-
ward phosphatidylserine (PS) residues. Annexin V and its
derivatives have been radiolabeled with a wide variety of ra-
dionuclides including radioiodine (123I, 124I, 125I), 18F, 99mTc,
111In, 11C, and 64Cu [73]. Radiolabeled caspase substrates,
inhibitors and monoclonal antibodies targeted to human An-
nexin V have also been reported as alternative approaches
for apoptosis imaging [74].
A recent report by Tait and coworkers has compared the
apoptosis-specific liver uptake of several 99mTc-labeled An-
nexin V derivatives prepared by amine-directed modification
with those labeled site-specifically at the N-terminus [75].
A clear improvement was seen for site specific labeling
as compared to amine-directed modification. Use of 99mTc-
labeled hydrazinenicotinamide-annexin V imaging for as-
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Fig. 13. Structure of 99mTc-HYNIC annexin V.
sessment of response to chemotherapy has also been re-
ported [76]. The reported imaging protocol was able to
distinguish responders from non-responders with 94% ac-
curacy (16/17 patients) and a sensitivity and specificity of
86% and 100%, respectively. 99mTc-labeled duramycin has
proved to have good affinity and selectivity for the PE tar-
get [77]. In these studies, 99mTc-HYNIC-duramycin showed
good binding to Jurkat cells induced into apoptosis follow-
ing camptothecin treatment. This binding could be competi-
tively abolished by the presence of PE containing liposomes,
but not by liposomes containing phosphatidylcholine (PC),
phosphatidylserine (PS), or phosphatidylglycerol (PG). The
results indicate that the binding of 99mTc-HYNIC-duramycin
to the apoptotic cells was exclusively and competitively di-
minished in the presence of increasing concentrations of
PE-containing liposomes, but not by liposomes consisting of
PC, PG, or PS.
Continued efforts in the identification of novel molecu-
lar targets involved in the apoptotic cascade could contribute
to new strategies that would allow early detection of the
process by means of specific cell death radiotracers. Fur-
thermore, the therapeutic (i.e. apoptosis inhibition) or toxic
(i.e. apoptosis induction) effect of new drugs can be evalu-
ated by means of specific apoptosis radiotracers. Such mark-
ers could also allow physicians to monitor the efficacy of
anti-cancer treatment and to select responding from non-
responding patients at an early stage of chemotherapy or
radiotherapy.
7. Discussion
SPECT has continued to dominate due to lower cost and
use of generator-based radionuclides as compared to PET,
which required higher infrastructure cost of cyclotron and
radiochemistry facilities. In this article, a review of SPECT
radiotracers in use and in development has been presented.
The applications of SPECT today range from the routine
cardiac myocardial perfusion imaging to receptor specific
tracers for oncology and neurology. The growth of SPECT
however faces its own challenges due to the shortage in sup-
ply of 99Mo and 99mTc arising out of the shutdown of the
reactor at Chalk River, which has adversely affected SPECT
users. It has also highlighted the need for SPECT users to
adopt alternative radionuclides such as 123I, 201Tl or 82Rb and
for manufacturers/suppliers of imaging agents to develop ra-
diotracers with alternative radiotracers. We have described
123I based radiotracers that have been launched in the market
and are currently used in Parkinson’s disease, cardiology and
neurology applications. While 123I requires a cyclotron, it is
not currently available outside of US, Europe and Japan and
an investment should be made in developing nations to pro-
vide this radionuclide as well as alternative radionuclides to
drive future radiotracer development for disease areas espe-
cially prevalent in developing nations.
In a recent review [78], the four challenges in the field of
radiotracer development described were: higher affinity ra-
diotracers, increasing the radiochemical specific activity to
reduce competitive binding, supply of 99mTc and moving ra-
diotracers from research to clinic to market.
Recent advances in chelation chemistry with newer
chelators such as the single amino acid chelators that are
analogues of lysine [79] and polyester dendrimer [80] that
could be labeled with technetium-99m are improving radio-
tracer kinetics through rapid blood clearance and reduced
background. As newer radiotracers are developed that target
specific receptors, chelation of 99mTc into small molecules
or peptides still poses challenges in chelator and pharma-
cophore size, affecting the overall affinity and clearance. In
a review of chelators for technetium and gallium radiotrac-
ers [81], recommendation was made for a design strategy
that takes into account the fundamental coordination chem-
istry of technetium and factors such as coordination prefer-
ences, robust core structures and ligand selection as these
are critical to creating effective radiotracers. For SPECT to
continue to be the modality of choice, better radiotracer de-
sign has to be combined with improvements in hardware to
improve image quality.
Valiant [78] also discussed the challenge of taking ra-
diotracers from the bench to the clinic. In this context, it
would be important to cite the example of infection imag-
ing which is an unmet need in many developing countries.
There have been various attempts to develop agents to image
infection using technetium labeled antibiotics, antimicrobial
peptides, and even anti-tuberculosis drugs, but none have
successfully been launched. The need today is to have the
infrastructure, technical expertise and support for system-
atic pre-clinical evaluations and clinical trials with adequate
follow up. This review of advancements in SPECT imaging
from hardware/software to new radiotracer development il-
lustrates that SPECT is still very much an attractive modality
for current and future disease applications.
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